Disease · MONDO_0005008

colorectal adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. colorectal adenocarcinoma. Diseases, record MONDO_0005008. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005008

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: colorectal adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005008; Open Targets
Other names: adenocarcinoma of large bowel, adenocarcinoma of large intestine, adenocarcinoma of the large bowel, adenocarcinoma of the large intestine, colon adenocarcinoma, colon carcinoma, colorectal (colon or rectal) adenocarcinoma, colorectal carcinoma, colorectal tumor, colorectum adenocarcinoma, large bowel adenocarcinoma, large intestine adenocarcinoma, rectal carcinoma; Open Targets
Disease Ontology: DOID:0050861; Disease Ontology
Disease Ontology: DOID:0050913; Disease Ontology
NCI Thesaurus: C5105; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 104 drugs, from DailyMed; Open Targets

Drugs104

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	DailyMed	23	22	22	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Approval	DailyMed	13	12	11	Drugs and targets
PANITUMUMAB	CHEMBL1201827	Antibody	Approval	DailyMed	6	5	5	Drugs and targets
TRIFLURIDINE	CHEMBL1129	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
TIPIRACIL HYDROCHLORIDE	CHEMBL65375	Small molecule	Approval	DailyMed	2	1	0	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	DailyMed	1	0	0	Drugs and targets
LEVOLEUCOVORIN CALCIUM	CHEMBL1908361	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	30	30	28	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	23	23	21	Drugs and targets

1 to 10 of 104

See all 104 drugs

Targets191

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
EGFR	Epidermal growth factor receptor	5	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
TYMS	Thymidylate synthase	5	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
CD274	Programmed cell death 1 ligand 1	4	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets

1 to 10 of 191

See all 191 targets

Trials111

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04322539	A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer	Phase 3	691	2023-09-14	Metastatic Colorectal Cancer, Metastatic Colon Cancer	FRUQUINTINIB	Its record names the disease	ClinicalTrials.gov
NCT02788279	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Phase 3	363	2019-06-18	Colorectal Cancer	ATEZOLIZUMAB, COBIMETINIB	Its record names the disease	ClinicalTrials.gov
NCT01479465	Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Phase 2	266	2019-04-17	Colorectal Cancer	SIMTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02599324	Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Phase 1/2	263	2022-10-26	Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma	CETUXIMAB, DOCETAXEL, EVEROLIMUS, IBRUTINIB, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00419159	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Phase 2	199	2011-05-16	Colorectal Cancer	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02870920	Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer	Phase 2	180	2021-01-19	Colorectal Cancer	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01516216	Study of Vitamin D in Untreated Metastatic Colorectal Cancer	Phase 2	139	2022-03-23	Metastatic Colorectal Cancer	BEVACIZUMAB, ERGOCALCIFEROL, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02509507	Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611	Phase 1/2	127	2022-12-30	Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors	PEMBROLIZUMAB, TALIMOGENE LAHERPAREPVEC	Its record names the disease	ClinicalTrials.gov
NCT00623805	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Phase 3	123	2014-08-08	Colorectal Cancer	BEVACIZUMAB, CAPECITABINE	Its record names the disease	ClinicalTrials.gov
NCT02368886	Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 2	123	2019-07-26	Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7	CLOBETASOL PROPIONATE, REGORAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 111

See all 111 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Fruquintinib + BSC Group vs Placebo + BSC Group: Health Care Resource Utilization: Number of Participants With Any Concomitant Medications Prescribed	116 of 461	63 of 230	691	NCT04322539	Trial comparisons
Fruquintinib + BSC Group vs Placebo + BSC Group: deaths from any cause	411 of 461	203 of 230	691	NCT04322539	Trial comparisons
Fruquintinib + BSC Group vs Placebo + BSC Group: serious adverse events	173 of 456	88 of 230	686	NCT04322539	Trial comparisons
Everolimus (RAD001) 70 mg/Week vs Everolimus (RAD001) 10 mg/Day: serious adverse events	34 of 99	22 of 100	199	NCT00419159	Trial comparisons
Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: deaths from any cause	54 of 61	100 of 118	179	NCT02870920	Trial comparisons
Best Supportive Care vs Durvalumab Plus Tremelimumab and Best Supportive Care: serious adverse events	0 of 61	55 of 118	179	NCT02870920	Trial comparisons
Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: deaths from any cause	54 of 67	45 of 68	135	NCT01516216	Trial comparisons
Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: serious adverse events	39 of 67	47 of 68	135	NCT01516216	Trial comparisons
Chemotherapy + Standard Dose Vitamin D vs Chemotherapy + Higher Dose Vitamin D: Number of Participants With Vitamin D Deficiency at Baseline	39 of 61	48 of 63	124	NCT01516216	Trial comparisons
Bevacizumab+Capecitabine+Oxaliplatin vs Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C: serious adverse events	12 of 62	21 of 61	123	NCT00623805	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials72

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32379280	RESULT	1	PubMed
32334940	RESULT	1	PubMed
29718089	RESULT	1	PubMed
24943235	RESULT	1	PubMed
22068656	RESULT	1	PubMed
21641867	RESULT	1	PubMed
21641636	RESULT	1	PubMed
21632455	RESULT	1	PubMed
21570111	RESULT	1	PubMed
21464401	RESULT	1	PubMed

1 to 10 of 72

See all 72 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005008

GET https://conductscience.org/api/diseases/v1/MONDO_0005008/drugs?page=2

API reference For AI assistants